Evidence map›Paper›PMID 40978485›Full record

SynthesisFrontiers in pharmacology2025

Protective role of exosomes in renal ischemia-reperfusion injury: a systematic review and meta-analysis.

Weibo Wang, Supeng Tai, Xi Cheng, Lexing Yang, Yifan Chang, Junyi Yan, Junyue Tao, Jun Zhou

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weibo Wang *Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Supeng Tai *Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Xi ChengDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Lexing YangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yifan ChangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Junyi YanDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Junyue TaoDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jun ZhouDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Renal ischemia-reperfusion injury (RIRI) is a major cause of acute kidney injury (AKI), commonly triggered by clinical procedures such as nephrectomy, renal transplantation, or shock resuscitation, and may progress to chronic kidney disease (CKD). Although exosomes hold promise as nanotherapeutics with pleiotropic mechanisms for renal protection, robust preclinical validation remains limited. This study aimed to clarify the therapeutic potential of exosome-based interventions for RIRI and to explore factors that modulate their efficacy. Methods: This systematic review and meta-analysis synthesized data from 19 controlled preclinical studies involving 245 rodents, retrieved from the PubMed, Web of Science, Embase, and Cochrane Library databases, to evaluate the therapeutic efficacy of exosomes in experimental RIRI models. Results: Exosome treatment led to broad therapeutic improvements in renal function, renal damage, inflammation, oxidative stress, apoptosis, pyroptosis, cellular proliferation, and fibrosis. Subgroup analyses identified exosomal source as a critical determinant of efficacy, with mesenchymal stem cell- and endothelial colony-forming cell-derived exosomes outperforming those from fibroblasts. No clear dose-response relationship was observed, and while pre-treatment initially appeared more effective than post-treatment, this difference was not significant after adjusting for confounders. Notably, different administration routes yielded comparable therapeutic outcomes. Discussion: These findings underscore the renoprotective potential of exosome therapy in RIRI and highlight the need for further investigation to optimize therapeutic protocols and accelerate clinical translation. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251008479, identifier PROSPERO, CRD420251008479.

Indexed as

dose-response relationshipsexosomesmesenchymal stem cellmeta-analysisrenal ischemia-reperfusion injury

Identifiers

PMID40978485
PMCPMC12443822

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.